

Resource Summary Report

Generated by [NIF](#) on Aug 30, 2026

Versiti Blood Research Institute Shared Resources Core Facility

RRID:SCR_025503

Type: Tool

Proper Citation

Versiti Blood Research Institute Shared Resources Core Facility (RRID:SCR_025503)

Resource Information

URL: <https://versiti.org/versiti-blood-research-institute/core-facilities-services>

Proper Citation: Versiti Blood Research Institute Shared Resources Core Facility (RRID:SCR_025503)

Description: Core forms network of laboratories dedicated to advancing biomedical research by providing access to specialized services, advanced equipment, and expert staff. Services include Bioinformatics, Biorepository, Flow Cytometry, Grant Application Support, Histology, Hybridoma, Microscopy, Molecular and Single Cell Biology, Protein Shared Instrumentation, Thrombosis and Hemostasis, Viral Vector.

Synonyms: , VBRI Shared Resources, Versiti Blood Research Institute Shared Resources

Resource Type: access service resource, core facility, service resource

Keywords: biomedical research, network of laboratories, specialized services, advanced equipment, expert staff,

Availability: Restricted

Resource Name: Versiti Blood Research Institute Shared Resources Core Facility

Resource ID: SCR_025503

Alternate IDs: ABRF_2865

Alternate URLs: <https://coremarketplace.org/?FacilityID=2865&citation=1>

Record Creation Time: 20240719T053249+0000

Record Last Update: 20260829T183406+0000

Ratings and Alerts

No rating or validation information has been found for Versiti Blood Research Institute Shared Resources Core Facility.

No alerts have been found for Versiti Blood Research Institute Shared Resources Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Yu H, et al. (2026) Impact of antiplatelet therapy on the hemostatic efficacy of platelet-targeted FVIII gene therapy in hemophilia A mice. *Blood advances*, 10(6), 1883.

Brzoska T, et al. (2026) CD39 polymorphism enables lung thrombosis in sickle cell disease. *Nature communications*, 17(1), 1693.

Witman N, et al. (2026) Atypical memory B cell clonal expansion and inflammatory programs associate with platelet-activating antibody development in COVID-19. *JCI insight*, 11(8).

Meinhardt NJ, et al. (2026) A method to unravel complexity in human peripheral blood B-cell subsets through multiomic cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) analyses. *ImmunoHorizons*, 10(2).

Zhou L, et al. (2026) Non-PF4/heparin-binding, platelet-activating antibodies in heparin-induced thrombocytopenia. *Blood*, 148(1), 115.

Yu M, et al. (2026) JMJD1C-mediated epigenetic control of autoimmunity and HIT antibody production. *Blood*.

Weich N, et al. (2026) Nascent preplatelets and B4GALT1 glycosylation contribute to 5-FU-induced bone marrow recovery. *Blood advances*, 10(14), 5045.

Murray JD, et al. (2026) Systematic benchmarking of CUT&Tag improves the reliability and reproducibility of chromatin analysis. *Cell reports methods*, 101499.

Beg MA, et al. (2025) Macrophage PIM1 Drives Atherosclerosis by Enhancing Foam Cell Formation Via CD36. *bioRxiv : the preprint server for biology*.

Shi Q, et al. (2025) The pivotal role of von Willebrand factor binding to platelet α IIb β 3 in stabilizing the formation of a platelet plug at sites of injury. *Haematologica*, 110(10), 2343.

Vats R, et al. (2025) Heme-Oxygenase 1 Mediated Activation of Cyp3A11 Protects Against Non-Steroidal Pain Analgesics Induced Acute Liver Damage in Sickle Cell Disease Mice. *Cells*, 14(3).

Zhang J, et al. (2025) Oxidized LDL stimulates PKM2-mediated mtROS production and phagocytosis. *Journal of lipid research*, 66(5), 100809.

Goncalves BS, et al. (2025) Na/K-ATPase Signaling in Adipocytes Promotes Atherosclerosis. *bioRxiv : the preprint server for biology*.

Warkentin TE, et al. (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. *The New England journal of medicine*, 332(20), 1330.